سعر سافيبلييد 500 مجم 20 قرص 2025

Savibleed 500 mg film-coated tablets (Marcyrl, Egypt), tranexamic acid 500 mg per tablet, pack of 20 tablets (2 strips); listed in Egypt as an antifibrinolytic for internal and external bleeding.

• Short-term use for haemorrhage or risk of haemorrhage in increased (local) fibrinolysis, e.g. prostatectomy and bladder surgery, menorrhagia, epistaxis, conisation of the cervix and traumatic hyphaemaelectronic medicines compendium (emc), UK
• Hereditary angioneurotic oedemaelectronic medicines compendium (emc), UK
• Management of dental extraction in haemophiliacselectronic medicines compendium (emc), UK

• Rare: colour vision disturbances, retinal/artery occlusion, thromboembolic events, allergic skin reactions; very rare: hypersensitivity including anaphylaxis, arterial or venous thrombosis, nausea/vomiting/diarrhoea; not known: convulsions, fixed drug eruption, acute renal cortical necrosis.International label, same formulation · electronic medicines compendium (emc), UK

• Severe renal impairment (risk of accumulation); hypersensitivity to tranexamic acid or excipients; active thromboembolic disease; history of venous or arterial thrombosis; fibrinolytic conditions following consumption coagulopathy; history of convulsions.International label, same formulation · electronic medicines compendium (emc), UK
• US label: contraindicated with concomitant combined hormonal contraceptives; active thromboembolic disease or a history or intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion; hypersensitivity to tranexamic acid.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Haematuria of upper urinary tract origin: risk of urinary obstruction; monitor closely.International label, same formulation · electronic medicines compendium (emc), UK
• Use with care with oral contraceptives (increased thrombosis risk) and in patients with previous thromboembolic events or thrombophilia only under strict supervision.International label, same formulation · electronic medicines compendium (emc), UK
• Irregular menstrual bleeding should be investigated before use; withdraw treatment if visual disturbance occurs; convulsions have been reported (mostly with high-dose IV use in cardiac surgery); not recommended in DIC-related fibrinolysis.International label, same formulation · electronic medicines compendium (emc), UK

• Fibrinolytic (thrombolytic) preparationsTranexamic acid counteracts the thrombolytic effect of fibrinolytic preparations.electronic medicines compendium (emc), UK
• Oral contraceptivesAdminister with care because of increased risk of thrombosis.electronic medicines compendium (emc), UK

• No evidence of teratogenic effect in animal studies, but the usual caution with drugs in pregnancy should be observed; tranexamic acid crosses the placenta.International label, same formulation · electronic medicines compendium (emc), UK
• Passes into breast milk at about one hundredth of the maternal blood concentration; an antifibrinolytic effect in the infant is unlikely.International label, same formulation · electronic medicines compendium (emc), UK

• Tranexamic acid: Blocks the lysine-binding sites of plasminogen, inhibiting plasminogen activation and plasmin-mediated fibrinolysis.